MAHLY.US Medipal Holdings Corp ADR
- Market cap
- USD 4.13B
- P/E
- 15.1x
- P/B
- 1.07x
- ROE
- 7.5%
- Dividend yield
- 2.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MAHLY.US undervalued?
Graham numberMAHLY.US trades 15.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medipal Holdings Corp ADR fundamental analysis
No fundamental analysis for Medipal Holdings Corp ADR yet.
Medipal Holdings Corp ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medipal Holdings Corp ADR
MediPal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. The company engages in the manufacture and supply of medical drugs, medical devices, medical supplies, clinical test reagents, and medical equipment and materials; non-life insurance agency business; outsourcing of medical office administration services; research and development of preventive medicine and cutting-edge medical technologies; and construction of a medical materi…
Full company profileMedipal Holdings Corp ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medipal Holdings Corp ADR annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.06T | 3.15T | 3.18T | 3.25T | 3.21T | 3.29T | 3.36T | 3.56T | 3.67T | 4.05T | 3.96T |
| Gross Profit | 207B | 215B | 221B | 224B | 201B | 205B | 212B | 247B | 256B | 262B | 250B |
| Operating Income | 39.3B | 44.3B | 49.5B | 53.1B | 38.6B | 45.6B | 49.0B | 47.3B | 55.6B | 56.4B | 49.0B |
| EBITDA | 53.1B | 59.6B | 77.6B | 90.4B | 53.4B | 60.0B | 63.6B | 65.3B | 95.2B | 86.3B | 67.7B |
| Net Income | 29.0B | 34.8B | 34.4B | 38.0B | 23.9B | 29.4B | 38.8B | 41.5B | 40.3B | 45.1B | 46.4B |
| EPS | 128 | 150 | 146 | 166 | 107 | 132 | 179 | 196 | 193 | 219 | 227 |
| Balance Sheet | |||||||||||
| Total Assets | 1.53T | 1.62T | 1.62T | 1.64T | 1.68T | 1.71T | 1.70T | 1.80T | 1.82T | 1.93T | 1.97T |
| Total Liabilities | 1.00T | 1.05T | 1.03T | 1.04T | 1.04T | 1.06T | 1.02T | 1.06T | 1.07T | 1.13T | 1.36T |
| Shareholders' Equity | 442B | 485B | 497B | 500B | 523B | 530B | 561B | 600B | 620B | 655B | 616B |
| Cash & Short-term Investments | 184B | 222B | 232B | 226B | 242B | 262B | 195B | 230B | 261B | 290B | 269B |
| Total Debt | 41.7B | 68.7B | 54.6B | 34.3B | 30.6B | 30.1B | 7.38B | 1.46B | 27.9M | - | 144B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 48.0B | 63.6B | 63.7B | 56.9B | 34.4B | 61.2B | 16.1B | 61.8B | 60.6B | 49.4B | - |
| Capital Expenditure | 35.8B | 30.5B | 18.5B | 27.4B | 15.7B | 18.9B | 13.5B | 19.4B | 12.4B | 7.02B | 12.2B |
| Free Cash Flow | 12.1B | 33.1B | 45.2B | 29.6B | 18.8B | 42.3B | 2.64B | 42.4B | 48.1B | 42.3B | - |
| Ratios | |||||||||||
| ROE | 6.6% | 7.2% | 6.9% | 7.6% | 4.6% | 5.5% | 6.9% | 6.9% | 6.5% | 6.9% | 7.5% |
| ROA | 1.9% | 2.1% | 2.1% | 2.3% | 1.4% | 1.7% | 2.3% | 2.3% | 2.2% | 2.3% | 2.4% |
| Net Profit Margin | 0.9% | 1.1% | 1.1% | 1.2% | 0.7% | 0.9% | 1.2% | 1.2% | 1.1% | 1.1% | 1.2% |
| Debt to Equity | 0.09x | 0.14x | 0.11x | 0.07x | 0.06x | 0.06x | 0.01x | 0.00x | 0.00x | - | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medipal Holdings Corp ADR dividends
- Dividend yield
- 2.07%
- Forward dividend
- 0.42 USD
- Payout ratio
- 31.1%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 14.0B | 68 | 31.1% |
| 2025 | JPY 12.5B | 60 | 31.1% |
| 2024 | JPY 11.2B | 53 | 27.0% |
| 2023 | JPY 9.66B | 45 | 24.9% |
| 2022 | USD 8.82B | 40 | 30.0% |
| 2021 | USD 8.82B | 40 | 36.9% |
| 2020 | USD 8.65B | 38 | 22.8% |
| 2019 | USD 8.05B | 34 | 23.4% |
| 2018 | JPY 7.22B | 31 | 20.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medipal Holdings Corp ADR
Ownership data of Medipal Holdings Corp ADR is not available yet.
Medipal Holdings Corp ADR company profile
- Company name
- Medipal Holdings Corp ADR
- Ticker
- MAHLY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 13,024
- Fiscal year end
- March
- Address
- 3-1-1 Kyobashi, Chuo, Japan, 104-8461
- Phone
- 81 3 3517 5800
- Website
- medipal.co.jp
About Medipal Holdings Corp ADR
MediPal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. The company engages in the manufacture and supply of medical drugs, medical devices, medical supplies, clinical test reagents, and medical equipment and materials; non-life insurance agency business; outsourcing of medical office administration services; research and development of preventive medicine and cutting-edge medical technologies; and construction of a medical materials database. It is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, the company offers management and marketing support for insurance pharmacies; logistics contract; veterinary medicines and feed additives; and food processing raw materials, food ingredients, food additives, and chemical product materials. It serves hospitals, clinics, pharmacies, drugstores, home centers, convenience store, supermarkets, veterinary clinics, livestock and fisheries businesses, processed food manufacturers, and other medical facilities. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to MediPal Holdings Corporation in October 2009. The company was founded in 1898 and is headquartered in Chuo, Japan.
Medipal Holdings Corp ADR management
7- Mr. Kuniaki ImagawaCEO, President, MD, Deputy Head of Pharmaceutical Business & Representative Director · born 1961
- Mr. Hiroshi YarimizuSenior Managing Executive Officer, Head of Financial Strategy & Director
- Mr. Toshihide YodaSenior MD of Investor Relations, GM of Business Development Department & Director · born 1963
- Mr. Shuichi WatanabeChief Compliance Officer & Representative Director · born 1952
- Toshiyuki IkeuchiExecutive Officer & Head of Corporate Communications Department, Corporate Planning Division
- Mr. Shinjiro WatanabeMD, GM of Corporate Planning Division, GM of Information Systems Management Division & Director · born 1972
- Mr. Yasuhiro ChoufukuExecutive VP & Representative Director · born 1954